SPHK1 and glioblastoma: These findings position the ENO1/TLR4-SPHK1/S1P axis as a metabolic-immune axis in GBM, where S1P sustains malignancy through autocrine signaling, expanding ENO1’s moonlighting functions and highlighting its therapeutic potential.